UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study

Hepatology (Baltimore, Md.), 2024-05

2024

Volltextzugriff (PDF)

Specificity of Short Interfering RNA Determined through Gene Expression Signatures

Proceedings of the National Academy of Sciences - PNAS, 2003-05, Vol.100 (11), p.6347-6352

2003

Volltextzugriff (PDF)

Assessment of Drug–Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations

Infectious diseases and therapy, 2023-08, Vol.12 (8), p.2057-2070

2023

Volltextzugriff (PDF)

A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax)

Molecular cancer therapeutics, 2010-11, Vol.9 (11), p.2943-2950

2010

Volltextzugriff (PDF)

Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways

Molecular cancer research, 2009-10, Vol.7 (10), p.1686-1692

2009

Volltextzugriff (PDF)

An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models

BMC genomics, 2010-06, Vol.3 (1), p.23-23, Article 23

2010

Volltextzugriff (PDF)

Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains

Molecular cancer research, 2007-04, Vol.5 (4), p.331-339

2007

Volltextzugriff (PDF)

Genomics in drug discovery and development

1, 2008

Volltextzugriff (PDF)

Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics

International journal of cancer, 2005-07, Vol.115 (4), p.528-538

2005

Volltextzugriff (PDF)

Endothelin signaling in osteoblasts: global genome view and implication of the calcineurin/NFAT pathway

Molecular cancer therapeutics, 2007-01, Vol.6 (1), p.253-261

2007

Volltextzugriff (PDF)

Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial

Alimentary pharmacology & therapeutics, 2022-06, Vol.55 (12), p.1512-1523

2022

Volltextzugriff (PDF)

Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection

Clinical gastroenterology and hepatology, 2019-02, Vol.17 (3), p.527-535.e6

2019

Volltextzugriff (PDF)

siRNA-mediated gene silencing: a global genome view

Nucleic acids research, 2004-01, Vol.32 (13), p.3836-3845

2004

Volltextzugriff (PDF)

Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Taking Concomitant Proton Pump Inhibitors: 2017 Presidential Poster Award: 970

The American journal of gastroenterology, 2017-10, Vol.112, p.S545-S546

2017

Volltextzugriff (PDF)

Abstract B4: A microRNA screen to identify modulators of sensitivity to Bcl-2 inhibitor ABT-263

Clinical cancer research, 2010-04, Vol.16 (7_Supplement), p.B4-B4

2010

Volltextzugriff (PDF)

Evaluating hypoxia-inducible factor-1α as a cancer therapeutic target via inducible RNA interference In vivo

Cancer research (Chicago, Ill.), 2005-08, Vol.65 (16), p.7249-7258

2005

Volltextzugriff (PDF)

Abstract A161: Acquired resistance to combination treatment with TMZ and ABT-888 is mediated by both BER and HR DNA repair pathways

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.A161-A161

2009

Volltextzugriff (PDF)

Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo

Cancer research (Chicago, Ill.), 2005-08, Vol.65 (16), p.7249-7258

2005

Volltextzugriff (PDF)

Genomic Biomarkers

Genomics in Drug Discovery and Development, 2008, p.105-166

2008

Volltextzugriff (PDF)

Genomics Technologies as Tools in Drug Discovery

Genomics in Drug Discovery and Development, 2008, p.25-103

2008

Volltextzugriff (PDF)

Introduction: Genomics and Personalized Medicine

Genomics in Drug Discovery and Development, 2008, p.1-24

2008

Volltextzugriff (PDF)

Germ Line Polymorphisms and Drug Response

Genomics in Drug Discovery and Development, 2008, p.329-383

2008

Volltextzugriff (PDF)

Fundamental Principles of Toxicogenomics

Genomics in Drug Discovery and Development, 2008, p.167-217

2008

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(29)

Publikationsform

Sprache

Englisch
(34)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study

Specificity of Short Interfering RNA Determined through Gene Expression Signatures

Assessment of Drug–Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations

A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax)

Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways

An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models

Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains

Genomics in drug discovery and development

Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics

Endothelin signaling in osteoblasts: global genome view and implication of the calcineurin/NFAT pathway

Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial

Eight-weeks of glecaprevir/pibrentasvir is well tolerated and yields high sustained virological response in HCV-infected treatment-naive patients with compensated cirrhosis: the CREST study

Healthcare resource utilization in treatment-naïve patients with compensated cirrhosis receiving 8-weeks’ glecaprevir/ pibrentasvir stratified by drug use and socioeconomic status: a retrospective chart review

Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection

siRNA-mediated gene silencing: a global genome view

Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Taking Concomitant Proton Pump Inhibitors: 2017 Presidential Poster Award: 970

Abstract B4: A microRNA screen to identify modulators of sensitivity to Bcl-2 inhibitor ABT-263

Evaluating hypoxia-inducible factor-1α as a cancer therapeutic target via inducible RNA interference In vivo

Abstract A161: Acquired resistance to combination treatment with TMZ and ABT-888 is mediated by both BER and HR DNA repair pathways

Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo

Genomic Biomarkers

Genomics Technologies as Tools in Drug Discovery

Introduction: Genomics and Personalized Medicine

Germ Line Polymorphisms and Drug Response

Fundamental Principles of Toxicogenomics

Suchergebnisse filtern